AKERO THERAPEUTICS INC (AKRO) Stock Price, Quote, News and Overview
NASDAQ:AKRO - Nasdaq - US00973Y1082 - Common Stock - Currency: USD
AKRO Quote, Performance and Key Statistics
AKERO THERAPEUTICS INC
NASDAQ:AKRO (2/4/2025, 8:26:04 PM)
After market: 57 +0.59 (+1.05%)56.41
+2.56 (+4.75%)
The current stock price of AKRO is 56.41 USD. In the past month the price increased by 99.75%. In the past year, price increased by 185.48%.
AKRO Latest News, Press Releases and Analysis
Which stocks are experiencing notable movement on Monday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
These stocks are moving in today's session
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Traders are paying attention to the gapping stocks in Monday's session.
Let's have a look at the gap up and gap down stocks in today's session.
These stocks that are showing activity before the opening bell on Monday.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners experiencing significant growth due to strategic developments.
AKRO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 14.58 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About AKRO
Company Profile
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 60 full-time employees. The company went IPO on 2019-06-20. The firm is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Company Info
AKERO THERAPEUTICS INC
601 Gateway Boulevard, Suite 350
South San Francisco CALIFORNIA 94080 US
CEO: Andrew Cheng
Employees: 61
Company Website: https://akerotx.com/
Investor Relations: https://ir.akerotx.com/
Phone: 16504876488
AKRO FAQ
What is the stock price of AKRO?
The current stock price of AKRO is 56.41 USD.
What is the symbol for AKERO THERAPEUTICS INC stock?
The exchange symbol of AKERO THERAPEUTICS INC is AKRO and it is listed on the Nasdaq exchange.
On which exchange is AKRO stock listed?
AKRO stock is listed on the Nasdaq exchange.
Is AKRO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AKRO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AKRO.
Does AKRO stock pay dividends?
AKRO does not pay a dividend.
What is the Price/Earnings (PE) ratio of AKRO?
AKRO does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.75).
What is the Short Interest ratio of AKRO stock?
The outstanding short interest for AKRO is 5.68% of its float.
AKRO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AKRO. When comparing the yearly performance of all stocks, AKRO is one of the better performing stocks in the market, outperforming 97.77% of all stocks.
AKRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AKRO. AKRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AKRO Financial Highlights
Over the last trailing twelve months AKRO reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS increased by -59.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.02% | ||
| ROE | -32.13% | ||
| Debt/Equity | 0.05 |
AKRO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to AKRO. The Buy consensus is the average rating of analysts ratings from 18 analysts.